1 week Ago By ABMN Staff
Norges Bank purchased a new stake in shares of Keros Therapeutics, Inc. ( NASDAQ:KROS – Free Report ) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 64,900 shares of the company’s stock, valued at approximately $1,027,000.
Other institutional investors also recently bought and sold shares of the company. AlphaQuest LLC boosted its position in shares of Keros Therapeutics by 469.0% during the fourth quarter.
AlphaQuest LLC now owns 3,596 shares of the company’s stock valued at $57,000 after buying an additional 2,964 shares during the period. KLP Kapitalforvaltning AS bought a new stake in shares of Keros Therapeutics during the 4th quarter worth approximately $90,000. Exchange Traded Concepts LLC purchased a new position in Keros Therapeutics during the 4th quarter valued at $99,000.
China Universal Asset Management Co. Ltd. grew its position in Keros Therapeutics by 19.
0% in the 4th quarter. China Universal Asset Management Co. Ltd.
now owns 8,589 shares of the company’s stock valued at $136,000 after acquiring an additional 1,372 shares during the last quarter. Finally, Handelsbanken Fonder AB increased its stake in Keros Therapeutics by 11.3% in the fourth quarter.
Handelsbanken Fonder AB now owns 10,800 shares of the company’s stock worth $171,000 after purchasing an additional 1,100 shares during the period. 71.56% of the stock is currently owned by institutional investors.
Keros Therapeutics Trading Down 0.5 % KROS opened at $12.18 on Friday.
The firm has a market cap of $494.05 million, a price-to-earnings ratio of -2.34 and a beta of 1.
39. Keros Therapeutics, Inc. has a 12 month low of $9.
12 and a 12 month high of $72.37. The stock has a fifty day moving average price of $10.
91 and a 200-day moving average price of $30.80. Analysts Set New Price Targets KROS has been the subject of a number of recent analyst reports.
Cantor Fitzgerald lowered shares of Keros Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Tuesday, January 21st. Piper Sandler reduced their target price on shares of Keros Therapeutics from $40.00 to $15.
00 and set an “overweight” rating on the stock in a research report on Friday, January 17th. Wedbush reiterated a “neutral” rating and issued a $15.00 price target on shares of Keros Therapeutics in a report on Tuesday, April 1st.
Truist Financial reduced their price objective on Keros Therapeutics from $43.00 to $25.00 and set a “buy” rating on the stock in a report on Wednesday.
Finally, Scotiabank decreased their target price on Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating for the company in a research report on Thursday, January 16th.
Six investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, Keros Therapeutics has an average rating of “Moderate Buy” and an average target price of $40.33.
Get Our Latest Analysis on KROS Keros Therapeutics Profile ( Free Report ) Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. See Also Want to see what other hedge funds are holding KROS? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Keros Therapeutics, Inc. ( NASDAQ:KROS – Free Report ). Receive News & Ratings for Keros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keros Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
